Ascorbic acid for treatment in CMT1A: what's next?

Affiliations

Comment

Marianne de Visser et al. Lancet Neurol. 2011 Apr.

. 2011 Apr;10(4):291-3.

doi: 10.1016/S1474-4422(11)70042-4.

¹ Department of Neurology, Academic Medical Centre, 1100 DD Amsterdam, Netherlands. m.devisser@amc.nl

No abstract available

Comment on

Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Radice D, Calabrese D, Hughes RA, Solari A; CMT-TRIAAL; CMT-TRAUK groups. Pareyson D, et al. Lancet Neurol. 2011 Apr;10(4):320-8. doi: 10.1016/S1474-4422(11)70025-4. Lancet Neurol. 2011. PMID: 21393063 Free PMC article. Clinical Trial.